Upper Tract Urothelial Carcinoma (UTUC) refers to malignant changes of the transitional urothelial cells lining the upper urothelial tract of the renal pelvis and ureter.

Read More >

Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to MIBC is between 20% and 30%.

Read More >

High-grade NMIBC is a highly aggressive form of bladder cancer.

Read More >

About UroGen Pharma

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 and UGN-102, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

Read More >

Clinical Trials


olympusThe OLYMPUS study

Optimized DeLivery of Mitomycin for Primary UTUC Study
Currently recruiting patients

Read further information on the clinical study



optimaThe OPTIMA study II

OPTimized Instillation of Mitomycin for BlAdder Cancer Treament
Commencement of patient recruitment planned for H1 2018